- Home
- IGA vs CGTX Comparison
IGA vs CGTX Comparison
Compare IGA & CGTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IGA
- CGTX
- Stock Information
- Founded
- IGA 2005
- CGTX 2007
- Country
- IGA United States
- CGTX United States
- Employees
- IGA N/A
- CGTX N/A
- Industry
- IGA Investment Managers
- CGTX Biotechnology: Pharmaceutical Preparations
- Sector
- IGA Finance
- CGTX Health Care
- Exchange
- IGA Nasdaq
- CGTX Nasdaq
- Market Cap
- IGA 151.6M
- CGTX 158.8M
- IPO Year
- IGA N/A
- CGTX 2021
- Fundamental
- Price
- IGA $9.94
- CGTX $1.83
- Analyst Decision
- IGA
- CGTX Strong Buy
- Analyst Count
- IGA 0
- CGTX 3
- Target Price
- IGA N/A
- CGTX $2.83
- AVG Volume (30 Days)
- IGA 42.3K
- CGTX 2.2M
- Earning Date
- IGA 01-01-0001
- CGTX 11-12-2025
- Dividend Yield
- IGA 8.93%
- CGTX N/A
- EPS Growth
- IGA N/A
- CGTX N/A
- EPS
- IGA N/A
- CGTX N/A
- Revenue
- IGA N/A
- CGTX N/A
- Revenue This Year
- IGA N/A
- CGTX N/A
- Revenue Next Year
- IGA N/A
- CGTX N/A
- P/E Ratio
- IGA N/A
- CGTX N/A
- Revenue Growth
- IGA N/A
- CGTX N/A
- 52 Week Low
- IGA $7.77
- CGTX $0.22
- 52 Week High
- IGA $8.88
- CGTX $3.83
- Technical
- Relative Strength Index (RSI)
- IGA 51.58
- CGTX 55.23
- Support Level
- IGA $9.71
- CGTX $1.67
- Resistance Level
- IGA $9.94
- CGTX $2.05
- Average True Range (ATR)
- IGA 0.11
- CGTX 0.16
- MACD
- IGA -0.01
- CGTX 0.03
- Stochastic Oscillator
- IGA 58.06
- CGTX 71.88
About IGA Voya Global Advantage and Premium Opportunity Fund of Beneficial Interest
Voya Global Advantage and Premium Opportunity Fund is a United States-based diversified, closed-end management investment company. The fund has two investment objectives. Its primary objective is to provide a high level of income, while the secondary objective is to seek capital appreciation. To achieve these objectives, the fund invests at least 80% of its managed assets in a portfolio of common stocks from various countries around the world, including the United States. Additionally, it uses an integrated derivatives strategies.
About CGTX Cognition Therapeutics Inc.
Cognition Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the discovery and development of, small-molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system and retina. Its product candidate CT1812, is an orally delivered, small-molecule antagonist designed to penetrate the blood-brain barrier and bind selectively to the S2R complex.